<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:42:27Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6619290" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6619290</identifier>
        <datestamp>2019-07-22</datestamp>
        <setSpec>blackwellopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Br J Haematol</journal-id>
              <journal-id journal-id-type="iso-abbrev">Br. J. Haematol</journal-id>
              <journal-id journal-id-type="doi">10.1111/(ISSN)1365-2141</journal-id>
              <journal-id journal-id-type="publisher-id">BJH</journal-id>
              <journal-title-group>
                <journal-title>British Journal of Haematology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0007-1048</issn>
              <issn pub-type="epub">1365-2141</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6619290</article-id>
              <article-id pub-id-type="pmcid">PMC6619290</article-id>
              <article-id pub-id-type="pmc-uid">6619290</article-id>
              <article-id pub-id-type="pmid">30919940</article-id>
              <article-id pub-id-type="doi">10.1111/bjh.15843</article-id>
              <article-id pub-id-type="publisher-id">BJH15843</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Research Paper</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Haematological Malignancy</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Lenalidomide plus rituximab (R<sup>2</sup>) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial</article-title>
                <alt-title alt-title-type="left-running-head">M. R. Becnel <italic>et al</italic></alt-title>
              </title-group>
              <contrib-group>
                <contrib id="bjh15843-cr-0001" contrib-type="author">
                  <name>
                    <surname>Becnel</surname>
                    <given-names>Melody R.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6295-5433</contrib-id>
                  <xref ref-type="aff" rid="bjh15843-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="bjh15843-cr-0002" contrib-type="author">
                  <name>
                    <surname>Nastoupil</surname>
                    <given-names>Loretta J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="bjh15843-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="bjh15843-cr-0003" contrib-type="author">
                  <name>
                    <surname>Samaniego</surname>
                    <given-names>Felipe</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6931-4583</contrib-id>
                  <xref ref-type="aff" rid="bjh15843-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="bjh15843-cr-0004" contrib-type="author">
                  <name>
                    <surname>Davis</surname>
                    <given-names>Richard E.</given-names>
                  </name>
                  <xref ref-type="aff" rid="bjh15843-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="bjh15843-cr-0005" contrib-type="author">
                  <name>
                    <surname>You</surname>
                    <given-names>M. J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="bjh15843-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="bjh15843-cr-0006" contrib-type="author">
                  <name>
                    <surname>Green</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <xref ref-type="aff" rid="bjh15843-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="bjh15843-cr-0007" contrib-type="author">
                  <name>
                    <surname>Hagemeister</surname>
                    <given-names>Fredrick B.</given-names>
                  </name>
                  <xref ref-type="aff" rid="bjh15843-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="bjh15843-cr-0008" contrib-type="author">
                  <name>
                    <surname>Fanale</surname>
                    <given-names>Michelle A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="bjh15843-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="bjh15843-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="bjh15843-cr-0009" contrib-type="author">
                  <name>
                    <surname>Fayad</surname>
                    <given-names>Luis E.</given-names>
                  </name>
                  <xref ref-type="aff" rid="bjh15843-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="bjh15843-cr-0010" contrib-type="author">
                  <name>
                    <surname>Westin</surname>
                    <given-names>Jason R.</given-names>
                  </name>
                  <xref ref-type="aff" rid="bjh15843-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="bjh15843-cr-0011" contrib-type="author">
                  <name>
                    <surname>Wang</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <xref ref-type="aff" rid="bjh15843-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="bjh15843-cr-0012" contrib-type="author">
                  <name>
                    <surname>Oki</surname>
                    <given-names>Yasuhiro</given-names>
                  </name>
                  <xref ref-type="aff" rid="bjh15843-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="bjh15843-cr-0013" contrib-type="author">
                  <name>
                    <surname>Forbes</surname>
                    <given-names>Sheryl G.</given-names>
                  </name>
                  <xref ref-type="aff" rid="bjh15843-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="bjh15843-cr-0014" contrib-type="author">
                  <name>
                    <surname>Feng</surname>
                    <given-names>Lei</given-names>
                  </name>
                  <xref ref-type="aff" rid="bjh15843-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="bjh15843-cr-0015" contrib-type="author">
                  <name>
                    <surname>Neelapu</surname>
                    <given-names>Sattva S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="bjh15843-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="bjh15843-cr-0016" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Fowler</surname>
                    <given-names>Nathan H.</given-names>
                  </name>
                  <address>
                    <email>nfowler@mdanderson.org</email>
                  </address>
                  <xref ref-type="aff" rid="bjh15843-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="bjh15843-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Department of Lymphoma/Myeloma</named-content>
                <institution>The University of Texas MD Anderson Cancer Center</institution>
                <named-content content-type="city">Houston</named-content>
                <named-content content-type="country-part">TX</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="bjh15843-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Department of Hematopathology</named-content>
                <institution>The University of Texas MD Anderson Cancer Center</institution>
                <named-content content-type="city">Houston</named-content>
                <named-content content-type="country-part">TX</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="bjh15843-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <institution>Seattle Genetics Inc.</institution>
                <named-content content-type="city">Bothell</named-content>
                <named-content content-type="country-part">WA</named-content>
                <country country="US">USA</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label>
Correspondence: Nathan H. Fowler, MD The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd #429, Houston, TX 77030‐4009, USA.<break/>
E‐mail: <email>nfowler@mdanderson.org</email><break/></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>28</day>
                <month>3</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>6</month>
                <year>2019</year>
              </pub-date>
              <volume>185</volume>
              <issue>5</issue>
              <issue-id pub-id-type="doi">10.1111/bjh.2019.185.issue-5</issue-id>
              <fpage>874</fpage>
              <lpage>882</lpage>
              <history>
                <date date-type="received">
                  <day>19</day>
                  <month>10</month>
                  <year>2018</year>
                </date>
                <date date-type="accepted">
                  <day>18</day>
                  <month>1</month>
                  <year>2019</year>
                </date>
              </history>
              <permissions>
                <!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2019 John Wiley & Sons Ltd <copyright-statement>-->
                <copyright-statement content-type="article-copyright">© 2019 The Authors. <italic>British Journal of Haematology</italic> published by British Society for Haematology and John Wiley &amp; Sons Ltd</copyright-statement>
                <license license-type="creativeCommonsBy-nc-nd">
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:BJH-185-874.pdf"/>
              <abstract id="bjh15843-abs-0001">
                <title>Summary</title>
                <p>Lack of consensus for first‐line marginal zone lymphoma (<styled-content style="fixed-case">MZL</styled-content>) treatment and toxicities associated with currently available systemic therapies have inspired evaluation of immunotherapeutic agents yielding robust outcomes with improved tolerability. We previously reported durable efficacy with first‐line lenalidomide and rituximab (R<sup>2</sup>) in follicular lymphoma, <styled-content style="fixed-case">MZL</styled-content> and small lymphocytic lymphoma with a subsequent long‐term follow‐up shown here in <styled-content style="fixed-case">MZL</styled-content> patients. This phase 2 investigator‐initiated study included previously untreated, stage <styled-content style="fixed-case">III</styled-content>/<styled-content style="fixed-case">IV MZL</styled-content> patients treated with lenalidomide 20 mg/day on days 1–21 and rituximab 375 mg/m<sup>2</sup> on day 1 of each 28‐day cycle, continuing in responders for ≥6–12 cycles. The primary endpoint was overall response rate (<styled-content style="fixed-case">ORR</styled-content>); secondary endpoints were complete and partial response (<styled-content style="fixed-case">CR</styled-content>,<styled-content style="fixed-case"> PR</styled-content>), safety, and progression‐free survival (<styled-content style="fixed-case">PFS</styled-content>). The <styled-content style="fixed-case">ORR</styled-content> was 93% with 70% attaining <styled-content style="fixed-case">CR</styled-content>/<styled-content style="fixed-case">CR</styled-content> unconfirmed. At median follow‐up of 75·1 months, median <styled-content style="fixed-case">PFS</styled-content> was 59·8 months and 5‐year <styled-content style="fixed-case">OS</styled-content> was 96%. Most non‐haematological adverse events (<styled-content style="fixed-case">AE</styled-content>) were grade 1/2. Grade 3 haematological <styled-content style="fixed-case">AE</styled-content>s were neutropenia (33%) and leucopenia (7%), and grade 4 were leucopenia (3%) and thrombocytopenia (3%). Two patients died of secondary malignancies; no treatment‐related fatalities occurred. With extended follow‐up, outcomes for <styled-content style="fixed-case">MZL</styled-content> patients receiving R<sup>2</sup> were robust with no unexpected late or delayed toxicities.</p>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="bjh15843-kwd-0001">marginal zone lymphoma</kwd>
                <kwd id="bjh15843-kwd-0002">lenalidomide</kwd>
                <kwd id="bjh15843-kwd-0003">non‐Hodgkin lymphoma</kwd>
                <kwd id="bjh15843-kwd-0004">phase 2</kwd>
                <kwd id="bjh15843-kwd-0005">rituximab</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>The University of Texas MD Anderson Cancer Center</funding-source>
                </award-group>
                <award-group>
                  <funding-source>Celgene Corporation</funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="2"/>
                <table-count count="2"/>
                <page-count count="9"/>
                <word-count count="6007"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>component-id</meta-name>
                  <meta-value>bjh15843</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>June 2019</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.5 mode:remove_FC converted:10.07.2019</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <fn-group id="bjhj15843-ntgp-0100">
                <fn id="bjhj15843-note-0100">
                  <p>[The copyright line for this article was changed on 9 July 2019 after original online publication]</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body>
            <p>Marginal zone lymphoma (MZL) is a relatively rare variant of indolent non‐Hodgkin lymphoma (NHL) that accounts for 10% of B‐cell lymphomas (The Non‐Hodgkin's Lymphoma Classification Project, <xref rid="bjh15843-bib-0020" ref-type="ref">1997</xref>, Zucca &amp; Bertoni, <xref rid="bjh15843-bib-0027" ref-type="ref">2016</xref>). Subtypes include nodal, extranodal and splenic MZL, which comprise 2%, 5–8% and 1% of NHL patients, respectively (Zucca &amp; Bertoni, <xref rid="bjh15843-bib-0027" ref-type="ref">2016</xref>). MZL is a disease of older adults, and presents with a median age of approximately 65 years old at diagnosis (Thieblemont <italic>et al</italic>, <xref rid="bjh15843-bib-0021" ref-type="ref">2016</xref>). Data from the Surveillance, Epidemiology, and End Results database report a 5‐year relative survival rate of 84% for MZL as a whole, 77% for nodal, 89% for extranodal lymphoma and 80% for splenic MZL (Olszewski &amp; Castillo, <xref rid="bjh15843-bib-0016" ref-type="ref">2013</xref>).</p>
            <p>The pathogenesis of MZL is largely associated with alterations in B‐cell receptor signalling in association with the immune microenvironment. Therapeutic targeting of these aberrant pathways has identified promising treatment strategies for MZL. Lenalidomide, a second‐generation immunomodulatory drug (IMiD<sup>®</sup>), has been effective in the treatment of various B‐cell lymphomas (Kiesewetter <italic>et al</italic>, <xref rid="bjh15843-bib-0013" ref-type="ref">2013</xref>; Fowler <italic>et al</italic>, <xref rid="bjh15843-bib-0009" ref-type="ref">2014</xref>; Han <italic>et al</italic>, <xref rid="bjh15843-bib-0011" ref-type="ref">2014</xref>). Lenalidomide enhances T‐cell proliferation, upregulates costimulatory molecules on the surface of malignant cells and modulates the activation of oncogenic signalling pathways, such as nuclear factor (NF)‐κB (Fowler <italic>et al</italic>, <xref rid="bjh15843-bib-0009" ref-type="ref">2014</xref>).</p>
            <p>Marginal zone lymphoma is often considered a chronic disease with a long natural history and no universally accepted standard of care. Typically, nodal MZL is treated similarly to follicular lymphoma (FL) with approaches such as observation, chemotherapy, immunotherapy and radiation, often selected based on such factors as comorbidity of the patient, and stage and pathogenesis of the disease (Kalpadakis <italic>et al</italic>, <xref rid="bjh15843-bib-0012" ref-type="ref">2013</xref>; Fowler <italic>et al</italic>, <xref rid="bjh15843-bib-0009" ref-type="ref">2014</xref>; Tadmor &amp; Polliack, <xref rid="bjh15843-bib-0019" ref-type="ref">2017</xref>).</p>
            <p>Several studies have evaluated the activity and tolerability of chemoimmunotherapy in patients with previously untreated, stage III/IV MZL. A randomized study of patients with extranodal MZL demonstrated that the addition of rituximab to chlorambucil <italic>versus</italic> chlorambucil alone improved the overall response rate (ORR) with significant differences in complete response (CR) (Zucca <italic>et al</italic>, <xref rid="bjh15843-bib-0028" ref-type="ref">2013</xref>). Long‐term outcomes failed to show significant differences, questioning the need for treatment in asymptomatic MZL patients. The BRIGHT study, which included treatment‐naïve patients with mixed indolent NHL, including MZL, demonstrated that bendamustine‐rituximab (BR) was noninferior to rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) or cyclophosphamide, vincristine and prednisone (R‐CVP) in terms of CR, and ORR favoured BR over R‐CHOP/R‐CVP (Flinn <italic>et al</italic>, <xref rid="bjh15843-bib-0008" ref-type="ref">2014</xref>). The StiL study, which compared BR and R‐CHOP in patients with mantle cell lymphoma and various types of indolent NHL (including 12–14% of MZL patients in each arm), showed a significant progression‐free survival (PFS) benefit overall, but no significance between MZL arms (Rummel <italic>et al</italic>, <xref rid="bjh15843-bib-0017" ref-type="ref">2013</xref>). Although these studies showed high initial responses, the lack of durable remissions in many patients supports the need for continued investigation of new agents and novel combinations to improve outcomes for these patients.</p>
            <p>Lenalidomide has shown clinically significant efficacy both in the first‐line and relapsed/refractory settings in multiple B‐cell lymphomas (Wiernik <italic>et al</italic>, <xref rid="bjh15843-bib-0022" ref-type="ref">2008</xref>; Habermann <italic>et al</italic>, <xref rid="bjh15843-bib-0010" ref-type="ref">2009</xref>; Witzig <italic>et al</italic>, <xref rid="bjh15843-bib-0024" ref-type="ref">2009</xref>, <xref rid="bjh15843-bib-0025" ref-type="ref">2011</xref>; Badoux <italic>et al</italic>, <xref rid="bjh15843-bib-0002" ref-type="ref">2011</xref>; Chen <italic>et al</italic>, <xref rid="bjh15843-bib-0004" ref-type="ref">2011</xref>), including MZL (Kiesewetter <italic>et al</italic>, <xref rid="bjh15843-bib-0013" ref-type="ref">2013</xref>). A phase 2 study showed that lenalidomide monotherapy in patients with extranodal MZL was well tolerated and demonstrated an ORR of 61% and a CR of 33% (Kiesewetter <italic>et al</italic>, <xref rid="bjh15843-bib-0013" ref-type="ref">2013</xref>). In recent years, the anti‐CD20 antibody rituximab has been the backbone of treatment for MZL. Kalpadakis <italic>et al</italic> (<xref rid="bjh15843-bib-0012" ref-type="ref">2013</xref>) reported a 5‐year overall survival (OS) of 92% and PFS of 73% in splenic MZL patients treated with rituximab monotherapy.</p>
            <p>We performed an investigator‐initiated, open‐label, phase 2 trial at MD Anderson Cancer Center to assess the efficacy and safety of R<sup>2</sup> in previously untreated patients with stage III or IV FL, MZL, or small lymphocytic lymphoma. The present report provides longer follow‐up at a median of 75·1 months, with efficacy and safety outcomes for the 30 patients with MZL. This longer follow‐up also allowed for assessment of the potential impact of patient subgroups on survival.</p>
            <sec id="bjh15843-sec-0002">
              <title>Patients and methods</title>
              <sec id="bjh15843-sec-0003">
                <title>Eligibility criteria</title>
                <p>Patients had a diagnosis of stage III or IV MZL, were aged ≥18 years and had Eastern Cooperative Oncology Group performance status &lt;2, absolute neutrophil count ≥1·5 × 10<sup>9</sup>/l, platelet count ≥100 × 10<sup>9</sup>/l and adequate organ function. Of note, patients were not required to meet Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria for treatment (Brice <italic>et al</italic>, <xref rid="bjh15843-bib-0003" ref-type="ref">1997</xref>; Salles <italic>et al</italic>, <xref rid="bjh15843-bib-0018" ref-type="ref">2011</xref>). Key exclusion criteria were a history of any malignancy within the previous 5 years, uncontrolled serious illness or comorbidities, human immunodeficiency virus infection, and active hepatitis B or C infection.</p>
              </sec>
              <sec id="bjh15843-sec-0004">
                <title>Study design</title>
                <p>This was a single‐institution phase 2 study of lenalidomide plus rituximab (i.e., R<sup>2</sup>) in previously untreated patients with advanced‐stage indolent NHL (ClinicalTrials.gov identifier: NCT00695786). Detailed methods have been previously described (Fowler <italic>et al</italic>, <xref rid="bjh15843-bib-0009" ref-type="ref">2014</xref>) and are briefly summarized here. An institutional review board approved this study, which was performed in accordance with the Declaration of Helsinki and good clinical practice guidelines. All patients provided written informed consent.</p>
                <p>Patients received oral lenalidomide at 20 mg/day on days 1–21 of each 28‐day cycle and were given rituximab at 375 mg/m<sup>2</sup> as an intravenous infusion on day 1 of each cycle. Patients with a tumour response after six cycles could, but were not required to, continue treatment for a maximum of 12 cycles as tolerated. Prophylactic growth factor support was not permitted.</p>
                <p>Responses were assessed according to 1999 International Working Group (IWG) criteria (Cheson <italic>et al</italic>, <xref rid="bjh15843-bib-0005" ref-type="ref">1999</xref>). Two independent radiologists reviewed equivocal findings. Physical examinations and computed tomography imaging were performed at study entry, every 3 months for 2 years, every 6 months in the third year, and yearly thereafter. To confirm CR, bone marrow biopsies were performed at 3 and 6 months.</p>
              </sec>
              <sec id="bjh15843-sec-0005">
                <title>Statistical analysis</title>
                <p>The primary endpoint was ORR, defined as the proportion of patients who exhibited a CR, CR unconfirmed (CRu) or partial response (PR) as per 1999 IWG criteria (Cheson <italic>et al</italic>, <xref rid="bjh15843-bib-0005" ref-type="ref">1999</xref>). Secondary endpoints included CR and PR rates, PFS (assessed from first treatment administration to disease progression or death due to any cause, whichever occurred first), OS (assessed from first treatment administration to death) and safety<italic><bold>.</bold></italic> Adverse events (AEs) were graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events version 3.0. (<ext-link ext-link-type="uri" xlink:href="http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf">http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf</ext-link>).</p>
                <p>The trial was initially designed as a phase 2 pilot study with 30 patients, but was later expanded to enrol 156 patients (30 patients with MZL) to further examine safety and efficacy<italic><bold>.</bold></italic> For the MZL cohort, the null hypothesis predicted ORR in no more than 70% of patients. The 30‐patient sample size for MZL was expected to achieve a width of 0·23 for the posterior 90% credibility interval under the assumption of an 80% ORR. All patients with any post‐baseline tumour assessment were assessed for response. Statistical assumptions based on MZL subtype and to compare among groups were not planned due to the small number of patients in each subgroup.</p>
                <p>In this analysis, we evaluated the associations between various categorical patient characteristics (age, sex, stage, B symptoms, splenomegaly, effusions/ascites, haemoglobin, absolute lymphocyte count, high tumour burden and whether GELF criteria for treatment were met) with response to R<sup>2</sup>, as well as the duration of disease control. Summary statistics, including mean, standard deviation, median and range for continuous variables, such as age and laboratory measurements, frequency counts and percentages for categorical variables, such as sex, stage, diagnosis and response, are provided. The chi‐square test or Fisher's exact test were used to evaluate the association between two categorical variables. Kruskal–Wallis test or Wilcoxon rank sum test was used to evaluate the difference in a continuous variable among or between patient groups.</p>
                <p>The Kaplan–Meier method was used for time‐to‐event analysis. For the PFS analysis, patients were censored at the last follow‐up date if neither progression nor death had occurred. For the OS analysis, patients were censored at the last follow‐up date if death had not occurred. Median time‐to‐event in months with 95% confidence interval (CI) was calculated. The log‐rank test was used to evaluate the difference in time‐to‐event endpoints between patient groups. Statistical software SAS 9.1.3 (SAS Institute, Cary, NC, USA) and S‐Plus 8.0 (TIBCO Software Inc. Palo Alto, CA, USA) were used for the analyses.</p>
              </sec>
            </sec>
            <sec id="bjh15843-sec-0006">
              <title>Results</title>
              <sec id="bjh15843-sec-0007">
                <title>Patient demographics</title>
                <p>The trial enrolled patients from 30 June 2008 to 12 August 2011. For 30 MZL patients, the median age was 58 years (range, 36–77) and 60% were female (Table <xref rid="bjh15843-tbl-0001" ref-type="table">1</xref>). MZL subtypes included 18 (60%) patients with nodal MZL, 11 (37%) with extranodal MZL/mucosa‐associated lymphoid tissue (MALT) lymphoma and 1 (3%) with splenic MZL. All MZL patients had stage III/IV disease, including 9 (30%) with stage III disease and 21 (70%) with stage IV.</p>
                <table-wrap id="bjh15843-tbl-0001" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 1</label>
                  <caption>
                    <p>Patient demographics and clinical characteristics (<italic>N </italic>=<italic> </italic>30)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">Characteristic</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <italic>n</italic>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1">%</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="3" rowspan="1">Age, years</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median</td>
                        <td align="char" char="." rowspan="1" colspan="1">58</td>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Range</td>
                        <td align="char" char="." rowspan="1" colspan="1">36–77</td>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" colspan="3" rowspan="1">Age</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">&lt;60 years</td>
                        <td align="char" char="." rowspan="1" colspan="1">17</td>
                        <td align="char" char="." rowspan="1" colspan="1">57</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">≥60 years</td>
                        <td align="char" char="." rowspan="1" colspan="1">13</td>
                        <td align="char" char="." rowspan="1" colspan="1">43</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="3" rowspan="1">Sex</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female</td>
                        <td align="char" char="." rowspan="1" colspan="1">18</td>
                        <td align="char" char="." rowspan="1" colspan="1">60</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male</td>
                        <td align="char" char="." rowspan="1" colspan="1">12</td>
                        <td align="char" char="." rowspan="1" colspan="1">40</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="3" rowspan="1">Diagnosis</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Nodal MZL</td>
                        <td align="char" char="." rowspan="1" colspan="1">18</td>
                        <td align="char" char="." rowspan="1" colspan="1">60</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Extranodal MZL/MALT lymphoma</td>
                        <td align="char" char="." rowspan="1" colspan="1">11</td>
                        <td align="char" char="." rowspan="1" colspan="1">37</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Splenic MZL</td>
                        <td align="char" char="." rowspan="1" colspan="1">1</td>
                        <td align="char" char="." rowspan="1" colspan="1">3</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="3" rowspan="1">Stage</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">III</td>
                        <td align="char" char="." rowspan="1" colspan="1">9</td>
                        <td align="char" char="." rowspan="1" colspan="1">30</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">IV</td>
                        <td align="char" char="." rowspan="1" colspan="1">21</td>
                        <td align="char" char="." rowspan="1" colspan="1">70</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">B symptoms</td>
                        <td align="char" char="." rowspan="1" colspan="1">3</td>
                        <td align="char" char="." rowspan="1" colspan="1">10</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Splenomegaly</td>
                        <td align="char" char="." rowspan="1" colspan="1">4</td>
                        <td align="char" char="." rowspan="1" colspan="1">13</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Pleural effusion/ascites</td>
                        <td align="char" char="." rowspan="1" colspan="1">2</td>
                        <td align="char" char="." rowspan="1" colspan="1">7</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="3" rowspan="1">Haemoglobin</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">&lt;120 g/l</td>
                        <td align="char" char="." rowspan="1" colspan="1">8</td>
                        <td align="char" char="." rowspan="1" colspan="1">27</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">≥120 g/l</td>
                        <td align="char" char="." rowspan="1" colspan="1">22</td>
                        <td align="char" char="." rowspan="1" colspan="1">73</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Lactate dehydrogenase (≤618)</td>
                        <td align="char" char="." rowspan="1" colspan="1">30</td>
                        <td align="char" char="." rowspan="1" colspan="1">100</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="3" rowspan="1">Absolute lymphocyte count</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">&lt;1·71 × 10<sup>9</sup>/l</td>
                        <td align="char" char="." rowspan="1" colspan="1">19</td>
                        <td align="char" char="." rowspan="1" colspan="1">63</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">≥1·71 × 10<sup>9</sup>/l</td>
                        <td align="char" char="." rowspan="1" colspan="1">11</td>
                        <td align="char" char="." rowspan="1" colspan="1">37</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">High tumour burden per GELF<xref ref-type="fn" rid="bjh15843-note-0002">*</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">2</td>
                        <td align="char" char="." rowspan="1" colspan="1">7</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Met GELF criteria<xref ref-type="fn" rid="bjh15843-note-0002">*</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">16</td>
                        <td align="char" char="." rowspan="1" colspan="1">53</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="bjh15843-note-0001">
                      <p>GELF, Groupe d'Etude des Lymphomes Folliculaires; MALT, mucosa‐associated lymphoid tissue; MZL, marginal zone lymphoma.</p>
                    </fn>
                    <fn id="bjh15843-note-0002">
                      <label>*</label>
                      <p>GELF criteria were defined according to previously published reports (Brice <italic>et al</italic>, <xref rid="bjh15843-bib-0003" ref-type="ref">1997</xref>; Salles <italic>et al</italic>, <xref rid="bjh15843-bib-0018" ref-type="ref">2011</xref>).</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
                <p>Median follow‐up for the study was 75·1 months (range, 16·2–100·2). The median duration of lenalidomide treatment was 6 months (range, 1–12 months; note, data for 1 patient were lost to follow‐up). Twenty‐four patients completed at least 6 cycles; 4 patients opted to proceed with 12 cycles of treatment; all 4 completed 12 cycles without early discontinuation. No patients discontinued therapy because of disease progression; 1 patient discontinued after 3 cycles secondary to stable disease, 3 (10%) discontinued secondary to AEs (rituximab intolerance), 2 discontinued due to patient preference based on intolerance to rituximab, and 4 were lost to long‐term follow‐up.</p>
              </sec>
              <sec id="bjh15843-sec-0008">
                <title>Safety</title>
                <p>A total of 6 patients required dose reductions of lenalidomide: 3 were reduced from 20 mg to 15 mg and the remaining 3 were reduced further to 10 mg. Adverse events experienced by all patients with MZL with mature follow‐up data included non‐haematological AEs (all grades) of fatigue (93%), nausea or vomiting (73%), cough/dyspnoea/pulmonary (63%), eye irritation (60%), pain or myalgia (60%), oedema (50%), constipation (47%), diarrhoea (47%) and rash (40%) (Fig <xref rid="bjh15843-fig-0001" ref-type="fig">1</xref>). No grade 4 non‐haematological AEs occurred. The most common grade 3 non‐haematological AEs were pain or myalgia (10%), cough/dyspnoea/pulmonary (7%) and rash (7%). Most AEs were manageable with a temporary hold of the medication or with supportive measures. Two patients required dose reduction of lenalidomide secondary to rash.</p>
                <fig fig-type="Figure" xml:lang="en" id="bjh15843-fig-0001" orientation="portrait" position="float">
                  <label>Figure 1</label>
                  <caption>
                    <p>Adverse events for all patients and all grades (<italic>N </italic>=<italic> </italic>30).</p>
                  </caption>
                  <graphic id="nlm-graphic-1" xlink:href="BJH-185-874-g001"/>
                </fig>
                <p>The most frequently reported any‐grade haematological AEs were neutropenia (60%), leucopenia (57%) and thrombocytopenia (37%). The only grade 4 haematological AEs were thrombocytopenia (3%) and leucopenia (3%). The only grade 3 haematological AEs were neutropenia (33%) and leucopenia (7%). Neutropenia was, overall, transient and able to be managed with a short treatment hold or dose reduction. Six patients required dose reductions of lenalidomide secondary to neutropenia, although it should be noted that 5 of these 6 patients required reduction only after 5 or more cycles of treatment. Growth factor support was administered to 8 patients per the provider's discretion. Despite neutropenia, no serious or life‐threatening infections were reported in any neutropenic patient. One patient developed sepsis secondary to pneumonia after cycle 2 but was not neutropenic at the time. No delayed infectious complications occurred after completion of treatment.</p>
              </sec>
              <sec id="bjh15843-sec-0009">
                <title>Efficacy</title>
                <p>The ORR among the 27 patients was 93%, including 19 (70%) patients with CR/CRu and 6 (22%) with PR (Table <xref rid="bjh15843-tbl-0002" ref-type="table">2</xref>). Patients underwent bone marrow biopsies to confirm responses. Among 16 patients with nodal MZL, 10 CRs/CRus occurred and ORR was 88%. Among 11 patients with extranodal MZL/MALT lymphoma, 8 CR/CRu responses contributed to an 80% ORR. The single patient with splenic MZL had a CR.</p>
                <table-wrap id="bjh15843-tbl-0002" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 2</label>
                  <caption>
                    <p>Response status by subtype in evaluable patients (<italic>n </italic>=<italic> </italic>27)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" valign="top" colspan="1">Subtype</th>
                        <th align="center" rowspan="2" valign="top" colspan="1">
                          <italic>n</italic>
                        </th>
                        <th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">ORR</th>
                        <th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">CR/CRu</th>
                        <th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">PR</th>
                        <th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">SD</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <italic>n</italic>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1">%</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <italic>n</italic>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1">%</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <italic>n</italic>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1">%</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <italic>n</italic>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1">%</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Nodal MZL<xref ref-type="fn" rid="bjh15843-note-0004">*</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">16</td>
                        <td align="char" char="." rowspan="1" colspan="1">16</td>
                        <td align="char" char="." rowspan="1" colspan="1">88</td>
                        <td align="char" char="." rowspan="1" colspan="1">10</td>
                        <td align="char" char="." rowspan="1" colspan="1">56</td>
                        <td align="char" char="." rowspan="1" colspan="1">4</td>
                        <td align="char" char="." rowspan="1" colspan="1">22</td>
                        <td align="char" char="." rowspan="1" colspan="1">2</td>
                        <td align="char" char="." rowspan="1" colspan="1">11</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Extranodal MZL/MALT lymphoma</td>
                        <td align="char" char="." rowspan="1" colspan="1">10</td>
                        <td align="char" char="." rowspan="1" colspan="1">10</td>
                        <td align="char" char="." rowspan="1" colspan="1">80</td>
                        <td align="char" char="." rowspan="1" colspan="1">8</td>
                        <td align="char" char="." rowspan="1" colspan="1">73</td>
                        <td align="char" char="." rowspan="1" colspan="1">0</td>
                        <td align="char" char="." rowspan="1" colspan="1">0</td>
                        <td align="char" char="." rowspan="1" colspan="1">2</td>
                        <td align="char" char="." rowspan="1" colspan="1">18</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Splenic MZL</td>
                        <td align="char" char="." rowspan="1" colspan="1">1</td>
                        <td align="char" char="." rowspan="1" colspan="1">1</td>
                        <td align="char" char="." rowspan="1" colspan="1">100</td>
                        <td align="char" char="." rowspan="1" colspan="1">1</td>
                        <td align="char" char="." rowspan="1" colspan="1">100</td>
                        <td align="char" char="." rowspan="1" colspan="1">0</td>
                        <td align="char" char="." rowspan="1" colspan="1">0</td>
                        <td align="char" char="." rowspan="1" colspan="1">0</td>
                        <td align="char" char="." rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">All patients</td>
                        <td align="char" char="." rowspan="1" colspan="1">27</td>
                        <td align="char" char="." rowspan="1" colspan="1">25</td>
                        <td align="char" char="." rowspan="1" colspan="1">93</td>
                        <td align="char" char="." rowspan="1" colspan="1">19</td>
                        <td align="char" char="." rowspan="1" colspan="1">70</td>
                        <td align="char" char="." rowspan="1" colspan="1">6</td>
                        <td align="char" char="." rowspan="1" colspan="1">22</td>
                        <td align="char" char="." rowspan="1" colspan="1">2</td>
                        <td align="char" char="." rowspan="1" colspan="1">7</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="bjh15843-note-0003">
                      <p>CR, complete response; CRu, CR unconfirmed; MALT, mucosa‐associated lymphoid tissue; MZL, marginal zone lymphoma; ORR, overall response rate; PR, partial response; SD, stable disease.</p>
                    </fn>
                    <fn id="bjh15843-note-0004">
                      <label>*</label>
                      <p>One patient with extranodal MZL and two patients with nodal MZL did not have a response analysis available.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
                <p>For all MZL patients, the median PFS was 59·8 months (95% CI, 50·6 to not reached) (Fig <xref rid="bjh15843-fig-0002" ref-type="fig">2</xref>A) and 5‐year PFS was 49% (95% CI, 32–73%), PFS rates were similar among various MZL subgroups (Fig <xref rid="bjh15843-fig-0002" ref-type="fig">2</xref>B–H and Figure <xref rid="bjh15843-sup-0001" ref-type="supplementary-material">S1</xref>). Median OS was not reached (Figure <xref rid="bjh15843-sup-0001" ref-type="supplementary-material">S2</xref>) and 5‐year OS was 96% (95% CI, 89–100%). OS rates were also similar among various MZL subgroups (Figure <xref rid="bjh15843-sup-0001" ref-type="supplementary-material">S2</xref>), with all subsets demonstrating an OS of at least 92% at 5 years. The current status of 27 patients at the last follow‐up is as follows: 25 (93%) are alive, 14 (52%) are in remission, 11 (41%) demonstrated progression/relapse and 2 (7%) have died due to secondary malignancies. One patient developed metastatic gastroesophageal junction carcinoma, and one patient (who was receiving fludarabine at the time of relapse) developed 3 malignancies, including T‐cell large granular lymphocytic leukaemia, smouldering multiple myeloma and carcinoma of unknown origin. Of the various patient characteristics assessed, none was significantly associated with ORR or CR outcome (data not shown).</p>
                <fig fig-type="Figure" xml:lang="en" id="bjh15843-fig-0002" orientation="portrait" position="float">
                  <label>Figure 2</label>
                  <caption>
                    <p>Kaplan–Meier curves for progression‐free survival (in all marginal zone lymphoma patients (A), by age (B), gender (C), disease stage (D), B symptoms (E), splenomegaly (F), pleural effusion/ascites (G) and haemoglobin [Hb] status (g/l; H). Time was calculated in months from the treatment start date to the progression date or death, whichever occurred first. Patients were censored at the last follow‐up date if neither progression nor death occurred. 95% confidence intervals are shown as broken lines in (A).</p>
                  </caption>
                  <graphic id="nlm-graphic-3" xlink:href="BJH-185-874-g002"/>
                </fig>
              </sec>
            </sec>
            <sec id="bjh15843-sec-0010">
              <title>Discussion</title>
              <p>As first‐line treatment for MZL, the combination of rituximab and lenalidomide was associated with favourable ORR, PFS and OS, and a manageable toxicity profile. Responses achieved were durable. With a median follow‐up of 75·1 months, the ORR was 93% for MZL patients, median PFS was 59·8 months and median OS has yet to be reached. With extended follow‐up, nearly all MZL patients treated with R<sup>2</sup> remain alive, the majority with no unexpected long‐term or delayed toxicity.</p>
              <p>These results are comparable with results from other studies of previously untreated MZL patients, although relatively little MZL‐specific data exist regarding the use of novel agents (Thieblemont <italic>et al</italic>, <xref rid="bjh15843-bib-0021" ref-type="ref">2016</xref>; Zucca &amp; Bertoni, <xref rid="bjh15843-bib-0027" ref-type="ref">2016</xref>). The International Extranodal Lymphoma Study Group (IELSG)‐19 study of rituximab combined with chlorambucil showed an ORR of 94%, 5‐year OS of 89% and 5‐year PFS of 71% (Zucca <italic>et al</italic>, <xref rid="bjh15843-bib-0028" ref-type="ref">2013</xref>). As part of larger studies of mixed indolent lymphoma patients, MZL‐specific data from the BRIGHT study of BR and R‐CHOP/CVP reported ORRs of 92% and 71%, respectively (Flinn <italic>et al</italic>, <xref rid="bjh15843-bib-0008" ref-type="ref">2014</xref>), whereas the StiL study reported a median PFS of 57·2 and 47·2 months for BR and R‐CHOP, respectively (Rummel <italic>et al</italic>, <xref rid="bjh15843-bib-0017" ref-type="ref">2013</xref>). Both lenalidomide and rituximab monotherapy have established activity in MZL patients. Lenalidomide monotherapy showed a 61% ORR (33% CR) in previously treated and treatment‐naïve patients with extranodal MALT lymphoma (Kiesewetter <italic>et al</italic>, <xref rid="bjh15843-bib-0013" ref-type="ref">2013</xref>). Five‐year OS of 92% and PFS of 73% have been reported in splenic MZL patients treated with rituximab monotherapy (Kalpadakis <italic>et al</italic>, <xref rid="bjh15843-bib-0012" ref-type="ref">2013</xref>). Results of the phase 3 Eastern Cooperative Oncology Group E4402 trial of rituximab maintenance versus retreatment strategies demonstrated an ORR for MZL patients of 52% and a superior time‐to‐treatment failure for maintenance rituximab over retreatment, but no difference in OS (Williams <italic>et al</italic>, <xref rid="bjh15843-bib-0023" ref-type="ref">2016</xref>).</p>
              <p>A phase 2 study of ibritumomab tiuxetan monotherapy in patients with previously untreated, non‐gastric, extranodal MZLs reported an 88% ORR at 12 weeks of therapy; with a median follow‐up of 65·6 months, median PFS was 47·6 months, median OS was not reached, 5‐year PFS was 40% and 5‐year OS was 72% (Lossos <italic>et al</italic>, <xref rid="bjh15843-bib-0014" ref-type="ref">2015</xref>). A phase 2 study of bortezomib added to R‐CHOP (VR‐CHOP) reported a 100% ORR, including 66% CR, 4‐year PFS of 83%, 4‐year OS of 93%, and 2 cases of grade 3 peripheral neuropathy (no grade 4) in 29 patients with previously untreated indolent NHL (Cohen <italic>et al</italic>, <xref rid="bjh15843-bib-0006" ref-type="ref">2015</xref>).</p>
              <p>Our results suggest that the combination of lenalidomide and rituximab as first‐line therapy for MZL achieves similar efficacy to that of currently available first‐line combinations. Additionally, R<sup>2</sup> treatment is well tolerated and responses are durable. These results suggest that rituximab can be combined with lenalidomide rather than standard chemotherapy without compromising efficacy.</p>
              <p>Notable limitations of this study include the small sample size and the inherent weaknesses of this being a single‐arm, non‐randomized study that was performed at a single centre located in the United States. MZL is a rare disease and, as such, the low number of patients limits the statistical power of these analyses. Additionally, response was assessed using 1999 IWG response criteria, which has advanced to include additional assessments (e.g., positron emission tomography imaging) to improve these analyses. Future global, randomized studies with a higher number of and more diverse patient population, and with updated response assessments, are needed to accurately compare R<sup>2</sup> with other first‐line treatment regimens for MZL.</p>
              <p>Ongoing phase 3 studies have been designed to continue to address the feasibility of R<sup>2</sup> in first‐line and relapsed/refractory indolent NHL. The AUGMENT study is examining R<sup>2</sup>
<italic>versus</italic> rituximab/placebo in patients with relapsed/refractory MZL and grade 1–3a FL (NCT01938001) to identify the potential additive benefit of R<sup>2</sup> over R. The MAGNIFY study adds in an analysis of lenalidomide or rituximab maintenance, while building more depth to the R<sup>2</sup> initial treatment data in relapsed/refractory FL, MZL, or mantle cell lymphoma (NCT01996865). An early look at the effects of the initial treatment phase of R<sup>2</sup> in MZL patients supports its efficacy and tolerability in this patient cohort (Coleman <italic>et al</italic>, <xref rid="bjh15843-bib-0007" ref-type="ref">2017</xref>). Phase 1 studies of single‐agent ibrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory patients with various B‐cell malignancies demonstrated an ORR of 60% with minimal AEs (Advani <italic>et al</italic>, <xref rid="bjh15843-bib-0001" ref-type="ref">2013</xref>). Noy <italic>et al</italic> (<xref rid="bjh15843-bib-0015" ref-type="ref">2017</xref>) reported an ORR of 48% in patients with MZL previously treated with rituximab. Additionally, <italic>in vitro</italic> combination of lenalidomide and ibrutinib demonstrated synergy via the downregulation of the transcription factor IRF4, which is important in NF‐κB signalling, a pathway vital in the pathogenesis of MZL (Yang <italic>et al</italic>, <xref rid="bjh15843-bib-0026" ref-type="ref">2012</xref>). Based on this information, our group has initiated an open‐label, phase 2 trial of the combination of R<sup>2</sup> and ibrutinib as first‐line treatment in MZL patients (NCT02532257).</p>
              <p>Results from this analysis also show that R<sup>2</sup> is well tolerated in patients with MZL. The most common non‐haematological AEs were grade 1 or 2, with a low number of grade 3 and no grade 4 non‐haematological AEs. Grade 3 haematological AEs consisted of neutropenia (33%) and leucopenia (7%), and the only grade 4 haematological AEs were thrombocytopenia (3%) and leucopenia (3%). Overall, these toxicities were manageable with supportive measures, and only a few patients required dose reductions of lenalidomide, mainly after 5 cycles or more. Despite this degree of neutropenia, no patient developed serious infectious complications, and the occurrences of neutropenia were transient in nature. To date, no patient has developed delayed infectious complications or marrow failure. We plan to further analyse the difference in the toxicity profile and efficacy among patients treated with 6 vs. 12 cycles of R<sup>2</sup>. To date, no long‐term toxicities related to treatment have been reported. Two patients developed secondary malignancies, but, based on the tumour histologies and additional patient risk factors, these were unlikely to be due to treatment with R<sup>2</sup>.</p>
              <p>In conclusion, the combination of R<sup>2</sup> has demonstrated significant efficacy, with an expected and manageable toxicity profile, in patients with previously untreated MZL. With extended follow‐up, most MZL patients receiving R<sup>2</sup> remain alive, with a median PFS of approximately 5 years, and no unexpected long‐term or delayed toxicities. Although first‐line R<sup>2</sup> treatment in treatment‐naïve MZL patients is well tolerated and associated with high response rates that are durable, further prospective studies are warranted to determine the potential biological rationale that could explain the differences in PFS and response in MZL compared with those seen in patients with FL.</p>
            </sec>
            <sec id="bjh15843-sec-0012">
              <title>Author contributions</title>
              <p>LJN, FS, RED, JY, FBH, MAF, LEF, JRW, MW, YO, SSN and NHF designed the study. MRB, LJN, RED, JY, SGF, FBH, JRW, MW, LF, SSN and NHF contributed to writing of the manuscript. All authors provided study materials and/or patients, collected and assembled the data, analysed and interpreted the data, and provided final approval of the manuscript.</p>
            </sec>
            <sec id="bjh15843-sec-0013">
              <title>Competing interests</title>
              <p>LJ Nastoupil reports honoraria, consulting or advisory role, and research funding from Celgene and Genentech. MA Fanale reports grants and personal consulting fees up to 4 June 2018 from Seattle Genetics and salary and stocks from 1 October 2018 following the start of her employment with Seattle Genetics. Grants and personal fees from Takeda, Celgene, BMS and Merck up to 4 June 2018, grants from ADC Therapeutics, Molecular Templates, MedImmune, Gilead and Genentech up to 4 June 2018, personal fees from Bayer and Spectrum up to 4 June 2018.JR Westin reports research funding from Janssen, Novartis, Kite Pharma, Celgene and Genentech. M Wang reports stock or other ownership from MoreHealth, honoraria from Janssen, AstraZeneca, Pharmacyclics, Dava Oncology and Celgene; consulting or advisory role from Janssen, AstraZeneca, MoreHealth, Medscape, IO Biotech, Nordic Biotech and BioInvent; research funding from Janssen, Pharmacyclics, AstraZeneca, Kite Pharma, Juno, BeiGene, Novartis, Celgene and Oncternal Therapeutics; and travel, accommodations, expenses from Janssen, Pharmacyclics, AstraZeneca and Celgene. Y Oki reports employment from Jazz Pharmaceuticals. SG Forbes reports consulting or advisory role from Gilead and Bayer. SS Neelapu reports consulting or advisory role and research funding from Celgene. NH Fowler reports consulting or advisory role from AbbVie, Janssen, Celgene and TG Therapeutics; research funding from AbbVie, Celgene, Janssen, and Roche and TG Therapeutics; and travel, accommodations, expenses from Celgene and Janssen. MR Becnel, F Samaniego, RE Davis, MJ You, M Green, FB Hagemeister, LE Fayad, and L Feng report no conflicts of interests.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="bjh15843-sup-0001">
                <caption>
                  <p><bold>Fig S1</bold>. Kaplan–Meier curves for progression‐free survival (PFS) in all MZL patients by absolute lymphocyte count (ALC) status (A), high tumor burden (B), and Groupe d'Etude des Lymphomes Folliculaires (GELF) (C).</p>
                  <p><bold>Fig S2</bold>. Kaplan–Meier curve for overall survival (OS) in all MZL patients (A), by age (B), gender (C), stage (D), B symptoms (E), splenomegaly (F), pleural effusion/ascites (G), hemoglobin status (H), absolute lymphocyte count (ALC) status (I), high tumor burden (J), and Groupe d'Etude des Lymphomes Folliculaires (GELF) (K).</p>
                </caption>
                <media xlink:href="BJH-185-874-s001.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="bjh15843-sec-0011">
              <title>Acknowledgements</title>
              <p>In addition to the many individuals in various departments at The University of Texas MD Anderson Cancer Center who worked diligently on the various aspects of this trial, the authors would like to thank the patients, families and caregivers who made this study possible. This work was sponsored by The University of Texas MD Anderson Cancer Center and received research funding from Celgene Corporation, Summit, NJ. Support for this study was funded in part by the MDACC Core grant. Editorial support in the preparation of this manuscript was provided by Bio Connections LLC and was funded by Celgene Corporation.</p>
            </ack>
            <ref-list content-type="cited-references" id="bjh15843-bibl-0001">
              <title>References</title>
              <ref id="bjh15843-bib-0001">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0001"><string-name><surname>Advani</surname>, <given-names>R.H.</given-names></string-name>, <string-name><surname>Buggy</surname>, <given-names>J.J.</given-names></string-name>, <string-name><surname>Sharman</surname>, <given-names>J.P.</given-names></string-name>, <string-name><surname>Smith</surname>, <given-names>S.M.</given-names></string-name>, <string-name><surname>Boyd</surname>, <given-names>T.E.</given-names></string-name>, <string-name><surname>Grant</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Kolibaba</surname>, <given-names>K.S.</given-names></string-name>, <string-name><surname>Furman</surname>, <given-names>R.R.</given-names></string-name>, <string-name><surname>Rodriguez</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Chang</surname>, <given-names>B.Y.</given-names></string-name>, <string-name><surname>Sukbuntherng</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Izumi</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Hamdy</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Hedrick</surname>, <given-names>E.</given-names></string-name> &amp; <string-name><surname>Fowler</surname>, <given-names>N.H.</given-names></string-name> (<year>2013</year>) <article-title>Bruton tyrosine kinase inhibitor ibrutinib (PCI‐32765) has significant activity in patients with relapsed/refractory B‐cell malignancies</article-title>. <source xml:lang="en">Journal of Clinical Oncology</source>, <volume>31</volume>, <fpage>88</fpage>–<lpage>94</lpage>.<pub-id pub-id-type="pmid">23045577</pub-id></mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0002">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0002"><string-name><surname>Badoux</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Keating</surname>, <given-names>M.J.</given-names></string-name>, <string-name><surname>Wen</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>B.N.</given-names></string-name>, <string-name><surname>Sivina</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Reuben</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Wierda</surname>, <given-names>W.G.</given-names></string-name>, <string-name><surname>O'Brien</surname>, <given-names>S.M.</given-names></string-name>, <string-name><surname>Faderl</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Kornblau</surname>, <given-names>S.M.</given-names></string-name>, <string-name><surname>Burger</surname>, <given-names>J.A.</given-names></string-name> &amp; <string-name><surname>Ferrajoli</surname>, <given-names>A.</given-names></string-name> (<year>2011</year>) <article-title>Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia</article-title>. <source xml:lang="en">Blood</source>, <volume>118</volume>, <fpage>3489</fpage>–<lpage>3498</lpage>.<pub-id pub-id-type="pmid">21725050</pub-id></mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0003">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0003"><string-name><surname>Brice</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Bastion</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Lepage</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Brousse</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Haioun</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Moreau</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Straetmans</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Tilly</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Tabah</surname>, <given-names>I.</given-names></string-name> &amp; <string-name><surname>Solal‐Celigny</surname>, <given-names>P.</given-names></string-name> (<year>1997</year>) <article-title>Comparison in low‐tumor‐burden follicular lymphomas between an initial no‐treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte</article-title>. <source xml:lang="en">Journal of Clinical Oncology</source>, <volume>15</volume>, <fpage>1110</fpage>–<lpage>1117</lpage>.<pub-id pub-id-type="pmid">9060552</pub-id></mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0004">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0004"><string-name><surname>Chen</surname>, <given-names>C.I.</given-names></string-name>, <string-name><surname>Bergsagel</surname>, <given-names>P.L.</given-names></string-name>, <string-name><surname>Paul</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Xu</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Lau</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Dave</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Kukreti</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Wei</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Leung‐Hagesteijn</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>Z.H.</given-names></string-name>, <string-name><surname>Brandwein</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Pantoja</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Johnston</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Gibson</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Hernandez</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Spaner</surname>, <given-names>D.</given-names></string-name> &amp; <string-name><surname>Trudel</surname>, <given-names>S.</given-names></string-name> (<year>2011</year>) <article-title>Single‐agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia</article-title>. <source xml:lang="en">Journal of Clinical Oncology</source>, <volume>29</volume>, <fpage>1175</fpage>–<lpage>1181</lpage>.<pub-id pub-id-type="pmid">21189385</pub-id></mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0005">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0005"><string-name><surname>Cheson</surname>, <given-names>B.D.</given-names></string-name>, <string-name><surname>Horning</surname>, <given-names>S.J.</given-names></string-name>, <string-name><surname>Coiffier</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Shipp</surname>, <given-names>M.A.</given-names></string-name>, <string-name><surname>Fisher</surname>, <given-names>R.I.</given-names></string-name>, <string-name><surname>Connors</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Lister</surname>, <given-names>T.A.</given-names></string-name>, <string-name><surname>Vose</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Grillo‐Lopez</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Hagenbeek</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Cabanillas</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Klippensten</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Hiddemann</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Castellino</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Harris</surname>, <given-names>N.L.</given-names></string-name>, <string-name><surname>Armitage</surname>, <given-names>J.O.</given-names></string-name>, <string-name><surname>Carter</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Hoppe</surname>, <given-names>R.</given-names></string-name> &amp; <string-name><surname>Canellos</surname>, <given-names>G.P.</given-names></string-name> (<year>1999</year>) <article-title>Report of an international workshop to standardize response criteria for non‐Hodgkin's lymphomas. NCI Sponsored International Working Group</article-title>. <source xml:lang="en">Journal of Clinical Oncology</source>, <volume>17</volume>, <fpage>1244</fpage>.<pub-id pub-id-type="pmid">10561185</pub-id></mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0006">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0006"><string-name><surname>Cohen</surname>, <given-names>J.B.</given-names></string-name>, <string-name><surname>Switchenko</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Koff</surname>, <given-names>J.L.</given-names></string-name>, <string-name><surname>Sinha</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Kaufman</surname>, <given-names>J.L.</given-names></string-name>, <string-name><surname>Khoury</surname>, <given-names>H.J.</given-names></string-name>, <string-name><surname>Bumpers</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Colbert</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Hutchison‐Rzepka</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Nastoupil</surname>, <given-names>L.J.</given-names></string-name>, <string-name><surname>Heffner</surname>, <given-names>L.T.</given-names></string-name>, <string-name><surname>Langston</surname>, <given-names>A.A.</given-names></string-name>, <string-name><surname>Lechowicz</surname>, <given-names>M.J.</given-names></string-name>, <string-name><surname>Lonial</surname>, <given-names>S.</given-names></string-name> &amp; <string-name><surname>Flowers</surname>, <given-names>C.R.</given-names></string-name> (<year>2015</year>) <article-title>A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non‐Hodgkin's lymphoma</article-title>. <source xml:lang="en">British Journal of Haematology</source>, <volume>171</volume>, <fpage>539</fpage>–<lpage>546</lpage>.<pub-id pub-id-type="pmid">26248505</pub-id></mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0007">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0007"><string-name><surname>Coleman</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Andorsky</surname>, <given-names>D.J.</given-names></string-name>, <string-name><surname>Yacoub</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Melear</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Kolibaba</surname>, <given-names>K.S.</given-names></string-name>, <string-name><surname>Brooks</surname>, <given-names>H.D.</given-names></string-name>, <string-name><surname>Bitran</surname>, <given-names>J.D.</given-names></string-name>, <string-name><surname>Fanning</surname>, <given-names>S.R.</given-names></string-name>, <string-name><surname>Lansigan</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Ricker</surname>, <given-names>J.L.</given-names></string-name>, <string-name><surname>Foon</surname>, <given-names>K.A.</given-names></string-name>, <string-name><surname>Llorente</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>J.</given-names></string-name> &amp; <string-name><surname>Sharman</surname>, <given-names>J.P.</given-names></string-name> (<year>2017</year>) <article-title>Phase IIIb study of lenalidomide plus rituximab followed by maintenance in relapsed or refractory NHL: analysis of marginal zone lymphoma</article-title>. <source xml:lang="en">Hematological Oncology (ICML meeting)</source>, <volume>35</volume>, <fpage>148</fpage>. (Abstract 139)</mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0008">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0008"><string-name><surname>Flinn</surname>, <given-names>I.W.</given-names></string-name>, <string-name><surname>van der Jagt</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Kahl</surname>, <given-names>B.S.</given-names></string-name>, <string-name><surname>Wood</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Hawkins</surname>, <given-names>T.E.</given-names></string-name>, <string-name><surname>Macdonald</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Hertzberg</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Kwan</surname>, <given-names>Y.L.</given-names></string-name>, <string-name><surname>Simpson</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Craig</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Kolibaba</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Issa</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Clementi</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Hallman</surname>, <given-names>D.M.</given-names></string-name>, <string-name><surname>Munteanu</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>L.</given-names></string-name> &amp; <string-name><surname>Burke</surname>, <given-names>J.M.</given-names></string-name> (<year>2014</year>) <article-title>Randomized trial of bendamustine‐rituximab or R‐CHOP/R‐CVP in first‐line treatment of indolent NHL or MCL: the BRIGHT study</article-title>. <source xml:lang="en">Blood</source>, <volume>123</volume>, <fpage>2944</fpage>–<lpage>2952</lpage>.<pub-id pub-id-type="pmid">24591201</pub-id></mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0009">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0009"><string-name><surname>Fowler</surname>, <given-names>N.H.</given-names></string-name>, <string-name><surname>Davis</surname>, <given-names>R.E.</given-names></string-name>, <string-name><surname>Rawal</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Nastoupil</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Hagemeister</surname>, <given-names>F.B.</given-names></string-name>, <string-name><surname>McLaughlin</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Kwak</surname>, <given-names>L.W.</given-names></string-name>, <string-name><surname>Romaguera</surname>, <given-names>J.E.</given-names></string-name>, <string-name><surname>Fanale</surname>, <given-names>M.A.</given-names></string-name>, <string-name><surname>Fayad</surname>, <given-names>L.E.</given-names></string-name>, <string-name><surname>Westin</surname>, <given-names>J.R.</given-names></string-name>, <string-name><surname>Shah</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Orlowski</surname>, <given-names>R.Z.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Turturro</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Oki</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Claret</surname>, <given-names>L.C.</given-names></string-name>, <string-name><surname>Feng</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Baladandayuthapani</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Muzzafar</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Tsai</surname>, <given-names>K.Y.</given-names></string-name>, <string-name><surname>Samaniego</surname>, <given-names>F.</given-names></string-name> &amp; <string-name><surname>Neelapu</surname>, <given-names>S.S.</given-names></string-name> (<year>2014</year>) <article-title>Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open‐label, phase 2 trial</article-title>. <source xml:lang="en">The Lancet Oncology</source>, <volume>15</volume>, <fpage>1311</fpage>–<lpage>1318</lpage>.<pub-id pub-id-type="pmid">25439689</pub-id></mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0010">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0010"><string-name><surname>Habermann</surname>, <given-names>T.M.</given-names></string-name>, <string-name><surname>Lossos</surname>, <given-names>I.S.</given-names></string-name>, <string-name><surname>Justice</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Vose</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Wiernik</surname>, <given-names>P.H.</given-names></string-name>, <string-name><surname>McBride</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Wride</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Ervin‐Haynes</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Takeshita</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Pietronigro</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Zeldis</surname>, <given-names>J.B.</given-names></string-name> &amp; <string-name><surname>Tuscano</surname>, <given-names>J.M.</given-names></string-name> (<year>2009</year>) <article-title>Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma</article-title>. <source xml:lang="en">British Journal of Haematology</source>, <volume>145</volume>, <fpage>344</fpage>–<lpage>349</lpage>.<pub-id pub-id-type="pmid">19245430</pub-id></mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0011">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0011"><string-name><surname>Han</surname>, <given-names>T.T.</given-names></string-name>, <string-name><surname>Fan</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>J.Y.</given-names></string-name> &amp; <string-name><surname>Xu</surname>, <given-names>W.</given-names></string-name> (<year>2014</year>) <article-title>Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy</article-title>. <source xml:lang="en">Cancer Biology &amp; Therapy</source>, <volume>15</volume>, <fpage>3</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">24149438</pub-id></mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0012">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0012"><string-name><surname>Kalpadakis</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Pangalis</surname>, <given-names>G.A.</given-names></string-name>, <string-name><surname>Angelopoulou</surname>, <given-names>M.K.</given-names></string-name>, <string-name><surname>Sachanas</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Kontopidou</surname>, <given-names>F.N.</given-names></string-name>, <string-name><surname>Yiakoumis</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Kokoris</surname>, <given-names>S.I.</given-names></string-name>, <string-name><surname>Dimitriadou</surname>, <given-names>E.M.</given-names></string-name>, <string-name><surname>Dimopoulou</surname>, <given-names>M.N.</given-names></string-name>, <string-name><surname>Moschogiannis</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Korkolopoulou</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Kyrtsonis</surname>, <given-names>M.C.</given-names></string-name>, <string-name><surname>Siakantaris</surname>, <given-names>M.P.</given-names></string-name>, <string-name><surname>Papadaki</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Tsaftaridis</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Plata</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Papadaki</surname>, <given-names>H.E.</given-names></string-name> &amp; <string-name><surname>Vassilakopoulos</surname>, <given-names>T.P.</given-names></string-name> (<year>2013</year>) <article-title>Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy</article-title>. <source xml:lang="en">The Oncologist</source>, <volume>18</volume>, <fpage>190</fpage>–<lpage>197</lpage>.<pub-id pub-id-type="pmid">23345547</pub-id></mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0013">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0013"><string-name><surname>Kiesewetter</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Troch</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Dolak</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Mullauer</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Lukas</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Zielinski</surname>, <given-names>C.C.</given-names></string-name> &amp; <string-name><surname>Raderer</surname>, <given-names>M.</given-names></string-name> (<year>2013</year>) <article-title>A phase II study of lenalidomide in patients with extranodal marginal zone B‐cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma)</article-title>. <source xml:lang="en">Haematologica</source>, <volume>98</volume>, <fpage>353</fpage>–<lpage>356</lpage>.<pub-id pub-id-type="pmid">22899582</pub-id></mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0014">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0014"><string-name><surname>Lossos</surname>, <given-names>I.S.</given-names></string-name>, <string-name><surname>Fabregas</surname>, <given-names>J.C.</given-names></string-name>, <string-name><surname>Koru‐Sengul</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Miao</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Goodman</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Serafini</surname>, <given-names>A.N.</given-names></string-name>, <string-name><surname>Hosein</surname>, <given-names>P.J.</given-names></string-name>, <string-name><surname>Stefanovic</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Rosenblatt</surname>, <given-names>J.D.</given-names></string-name> &amp; <string-name><surname>Hoffman</surname>, <given-names>J.E.</given-names></string-name> (<year>2015</year>) <article-title>Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma</article-title>. <source xml:lang="en">Leukemia &amp; Lymphoma</source>, <volume>56</volume>, <fpage>1750</fpage>–<lpage>1755</lpage>.<pub-id pub-id-type="pmid">25315074</pub-id></mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0015">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0015"><string-name><surname>Noy</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>de Vos</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Thieblemont</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Martin</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Flowers</surname>, <given-names>C.R.</given-names></string-name>, <string-name><surname>Morschhauser</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Collins</surname>, <given-names>G.P.</given-names></string-name>, <string-name><surname>Ma</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Coleman</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Peles</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Smith</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Barrientos</surname>, <given-names>J.C.</given-names></string-name>, <string-name><surname>Smith</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Munneke</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Dimery</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Beaupre</surname>, <given-names>D.M.</given-names></string-name> &amp; <string-name><surname>Chen</surname>, <given-names>R.</given-names></string-name> (<year>2017</year>) <article-title>Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma</article-title>. <source xml:lang="en">Blood</source>, <volume>129</volume>, <fpage>2224</fpage>–<lpage>2232</lpage>.<pub-id pub-id-type="pmid">28167659</pub-id></mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0016">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0016"><string-name><surname>Olszewski</surname>, <given-names>A.J.</given-names></string-name> &amp; <string-name><surname>Castillo</surname>, <given-names>J.J.</given-names></string-name> (<year>2013</year>) <article-title>Survival of patients with marginal zone lymphoma: analysis of the surveillance, epidemiology, and end results database</article-title>. <source xml:lang="en">Cancer</source>, <volume>119</volume>, <fpage>629</fpage>–<lpage>638</lpage>.<pub-id pub-id-type="pmid">22893605</pub-id></mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0017">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0017"><string-name><surname>Rummel</surname>, <given-names>M.J.</given-names></string-name>, <string-name><surname>Niederle</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Maschmeyer</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Banat</surname>, <given-names>G.A.</given-names></string-name>, <string-name><surname>von Grunhagen</surname>, <given-names>U.</given-names></string-name>, <string-name><surname>Losem</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Kofahl‐Krause</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Heil</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Welslau</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Balser</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Kaiser</surname>, <given-names>U.</given-names></string-name>, <string-name><surname>Weidmann</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Durk</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Ballo</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Stauch</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Roller</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Barth</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Hoelzer</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Hinke</surname>, <given-names>A.</given-names></string-name> &amp; <string-name><surname>Brugger</surname>, <given-names>W.</given-names></string-name> (<year>2013</year>) <article-title>Bendamustine plus rituximab versus CHOP plus rituximab as first‐line treatment for patients with indolent and mantle‐cell lymphomas: an open‐label, multicentre, randomised, phase 3 non‐inferiority trial</article-title>. <source xml:lang="en">The Lancet</source>, <volume>381</volume>, <fpage>1203</fpage>–<lpage>1210</lpage>.</mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0018">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0018"><string-name><surname>Salles</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Seymour</surname>, <given-names>J.F.</given-names></string-name>, <string-name><surname>Offner</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Lopez‐Guillermo</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Belada</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Xerri</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Feugier</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Bouabdallah</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Catalano</surname>, <given-names>J.V.</given-names></string-name>, <string-name><surname>Brice</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Caballero</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Haioun</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Pedersen</surname>, <given-names>L.M.</given-names></string-name>, <string-name><surname>Delmer</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Simpson</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Leppa</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Soubeyran</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Hagenbeek</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Casasnovas</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Intragumtornchai</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Ferme</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>da Silva</surname>, <given-names>M.G.</given-names></string-name>, <string-name><surname>Sebban</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Lister</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Estell</surname>, <given-names>J.A.</given-names></string-name>, <string-name><surname>Milone</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Sonet</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Mendila</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Coiffier</surname>, <given-names>B.</given-names></string-name> &amp; <string-name><surname>Tilly</surname>, <given-names>H.</given-names></string-name> (<year>2011</year>) <article-title>Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial</article-title>. <source xml:lang="en">The Lancet</source>, <volume>377</volume>, <fpage>42</fpage>–<lpage>51</lpage>.</mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0019">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0019"><string-name><surname>Tadmor</surname>, <given-names>T.</given-names></string-name> &amp; <string-name><surname>Polliack</surname>, <given-names>A.</given-names></string-name> (<year>2017</year>) <article-title>Nodal marginal zone lymphoma: clinical features, diagnosis, management and treatment</article-title>. <source xml:lang="en">Best Practice &amp; Research Clinical Haematology</source>, <volume>30</volume>, <fpage>92</fpage>–<lpage>98</lpage>.<pub-id pub-id-type="pmid">28288722</pub-id></mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0020">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0020"><collab collab-type="authors">The Non‐Hodgkin's Lymphoma Classification Project</collab>
(<year>1997</year>) <article-title>A clinical evaluation of the International Lymphoma Study Group classification of non‐Hodgkin's lymphoma. The Non‐Hodgkin's Lymphoma Classification Project</article-title>. <source xml:lang="en">Blood</source>, <volume>89</volume>, <fpage>3909</fpage>–<lpage>3918</lpage>.<pub-id pub-id-type="pmid">9166827</pub-id></mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0021">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0021"><string-name><surname>Thieblemont</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Molina</surname>, <given-names>T.</given-names></string-name> &amp; <string-name><surname>Davi</surname>, <given-names>F.</given-names></string-name> (<year>2016</year>) <article-title>Optimizing therapy for nodal marginal zone lymphoma</article-title>. <source xml:lang="en">Blood</source>, <volume>127</volume>, <fpage>2064</fpage>–<lpage>2071</lpage>.<pub-id pub-id-type="pmid">26989202</pub-id></mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0022">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0022"><string-name><surname>Wiernik</surname>, <given-names>P.H.</given-names></string-name>, <string-name><surname>Lossos</surname>, <given-names>I.S.</given-names></string-name>, <string-name><surname>Tuscano</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Justice</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Vose</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Cole</surname>, <given-names>C.E.</given-names></string-name>, <string-name><surname>Lam</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>McBride</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Wride</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Pietronigro</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Takeshita</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Ervin‐Haynes</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Zeldis</surname>, <given-names>J.B.</given-names></string-name> &amp; <string-name><surname>Habermann</surname>, <given-names>T.M.</given-names></string-name> (<year>2008</year>) <article-title>Lenalidomide monotherapy in relapsed or refractory aggressive non‐Hodgkin's lymphoma</article-title>. <source xml:lang="en">Journal of Clinical Oncology</source>, <volume>26</volume>, <fpage>4952</fpage>–<lpage>4957</lpage>.<pub-id pub-id-type="pmid">18606983</pub-id></mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0023">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0023"><string-name><surname>Williams</surname>, <given-names>M.E.</given-names></string-name>, <string-name><surname>Hong</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Gascoyne</surname>, <given-names>R.D.</given-names></string-name>, <string-name><surname>Wagner</surname>, <given-names>L.I.</given-names></string-name>, <string-name><surname>Krauss</surname>, <given-names>J.C.</given-names></string-name>, <string-name><surname>Habermann</surname>, <given-names>T.M.</given-names></string-name>, <string-name><surname>Swinnen</surname>, <given-names>L.J.</given-names></string-name>, <string-name><surname>Schuster</surname>, <given-names>S.J.</given-names></string-name>, <string-name><surname>Peterson</surname>, <given-names>C.G.</given-names></string-name>, <string-name><surname>Sborov</surname>, <given-names>M.D.</given-names></string-name>, <string-name><surname>Martin</surname>, <given-names>S.E.</given-names></string-name>, <string-name><surname>Weiss</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Ehmann</surname>, <given-names>W.C.</given-names></string-name>, <string-name><surname>Horning</surname>, <given-names>S.J.</given-names></string-name> &amp; <string-name><surname>Kahl</surname>, <given-names>B.S.</given-names></string-name> (<year>2016</year>) <article-title>Rituximab extended schedule or retreatment trial for low tumour burden non‐follicular indolent B‐cell non‐Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402</article-title>. <source xml:lang="en">British Journal of Haematology</source>, <volume>173</volume>, <fpage>867</fpage>–<lpage>875</lpage>.<pub-id pub-id-type="pmid">26970533</pub-id></mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0024">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0024"><string-name><surname>Witzig</surname>, <given-names>T.E.</given-names></string-name>, <string-name><surname>Wiernik</surname>, <given-names>P.H.</given-names></string-name>, <string-name><surname>Moore</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Reeder</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Cole</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Justice</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Kaplan</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Voralia</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Pietronigro</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Takeshita</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Ervin‐Haynes</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Zeldis</surname>, <given-names>J.B.</given-names></string-name> &amp; <string-name><surname>Vose</surname>, <given-names>J.M.</given-names></string-name> (<year>2009</year>) <article-title>Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non‐Hodgkin's Lymphoma</article-title>. <source xml:lang="en">Journal of Clinical Oncology</source>, <volume>27</volume>, <fpage>5404</fpage>–<lpage>5409</lpage>.<pub-id pub-id-type="pmid">19805688</pub-id></mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0025">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0025"><string-name><surname>Witzig</surname>, <given-names>T.E.</given-names></string-name>, <string-name><surname>Vose</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Zinzani</surname>, <given-names>P.L.</given-names></string-name>, <string-name><surname>Reeder</surname>, <given-names>C.B.</given-names></string-name>, <string-name><surname>Buckstein</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Polikoff</surname>, <given-names>J.A.</given-names></string-name>, <string-name><surname>Bouabdallah</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Haioun</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Tilly</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Guo</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Pietronigro</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Ervin‐Haynes</surname>, <given-names>A.L.</given-names></string-name> &amp; <string-name><surname>Czuczman</surname>, <given-names>M.S.</given-names></string-name> (<year>2011</year>) <article-title>An international phase II trial of single‐agent lenalidomide for relapsed or refractory aggressive B‐cell non‐Hodgkin's lymphoma</article-title>. <source xml:lang="en">Annals of Oncology</source>, <volume>22</volume>, <fpage>1622</fpage>–<lpage>1627</lpage>. <pub-id pub-id-type="pmid">21228334</pub-id></mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0026">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0026"><string-name><surname>Yang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Shaffer</surname>, <given-names>A.L.</given-names><suffix>3rd</suffix></string-name>, <string-name><surname>Emre</surname>, <given-names>N.C.</given-names></string-name>, <string-name><surname>Ceribelli</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Wright</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Xiao</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Powell</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Platig</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Kohlhammer</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Young</surname>, <given-names>R.M.</given-names></string-name>, <string-name><surname>Zhao</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Yang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Xu</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Buggy</surname>, <given-names>J.J.</given-names></string-name>, <string-name><surname>Balasubramanian</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Mathews</surname>, <given-names>L.A.</given-names></string-name>, <string-name><surname>Shinn</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Guha</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Ferrer</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Thomas</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Waldmann</surname>, <given-names>T.A.</given-names></string-name> &amp; <string-name><surname>Staudt</surname>, <given-names>L.M.</given-names></string-name> (<year>2012</year>) <article-title>Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma</article-title>. <source xml:lang="en">Cancer Cell</source>, <volume>21</volume>, <fpage>723</fpage>–<lpage>737</lpage>.<pub-id pub-id-type="pmid">22698399</pub-id></mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0027">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0027"><string-name><surname>Zucca</surname>, <given-names>E.</given-names></string-name> &amp; <string-name><surname>Bertoni</surname>, <given-names>F.</given-names></string-name> (<year>2016</year>) <article-title>The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance</article-title>. <source xml:lang="en">Blood</source>, <volume>127</volume>, <fpage>2082</fpage>–<lpage>2092</lpage>.<pub-id pub-id-type="pmid">26989205</pub-id></mixed-citation>
              </ref>
              <ref id="bjh15843-bib-0028">
                <mixed-citation publication-type="journal" id="bjh15843-cit-0028"><string-name><surname>Zucca</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Conconi</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Laszlo</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Lopez‐Guillermo</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Bouabdallah</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Coiffier</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Sebban</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Jardin</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Vitolo</surname>, <given-names>U.</given-names></string-name>, <string-name><surname>Morschhauser</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Pileri</surname>, <given-names>S.A.</given-names></string-name>, <string-name><surname>Copie‐Bergman</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Campo</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Jack</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Floriani</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Johnson</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Martelli</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Cavalli</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Martinelli</surname>, <given-names>G.</given-names></string-name> &amp; <string-name><surname>Thieblemont</surname>, <given-names>C.</given-names></string-name> (<year>2013</year>) <article-title>Addition of rituximab to chlorambucil produces superior event‐free survival in the treatment of patients with extranodal marginal‐zone B‐cell lymphoma: 5‐year analysis of the IELSG‐19 randomized study</article-title>. <source xml:lang="en">Journal of Clinical Oncology</source>, <volume>31</volume>, <fpage>565</fpage>–<lpage>572</lpage>.<pub-id pub-id-type="pmid">23295789</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
